These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 15177848

  • 1. Mechanisms of resistance among respiratory tract pathogens.
    Jacobs MR, Anon J, Appelbaum PC.
    Clin Lab Med; 2004 Jun; 24(2):419-53. PubMed ID: 15177848
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF, Brown NP, Thornsberry C, Jones ME.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
    Mendes C, Kiffer CR, Blosser-Middleton RS, Jones ME, Karlowsky JA, Barth A, Rossi F, Andrade S, Sader HS, Thornsberry C, Sahm DF, GLOBAL Surveillance Initiative 2001-2002.
    Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens.
    Alpuche C, Garau J, Lim V.
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S135-8. PubMed ID: 17945468
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections.
    Nicolau DP.
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S381-8. PubMed ID: 15603247
    [No Abstract] [Full Text] [Related]

  • 16. Resistance patterns of selected respiratory tract pathogens in Poland.
    Skoczyńska A, Kadłubowski M, Waśko I, Fiett J, Hryniewicz W.
    Clin Microbiol Infect; 2007 Apr; 13(4):377-83. PubMed ID: 17359321
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.